Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | GCNT3 |
| Gene Name: | GCNT3 |
| Protein Full Name: | Beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1 |
| Alias: | C2GnT-mucin type;Core 2/core 4 beta-1,6-N-acetylglucosaminyltransferase |
| Mass (Da): | 50864 |
| Number AA: | 438 |
| UniProt ID: | O95395 |
| Locus ID: | 9245 |
| COSMIC ID: | GCNT3 |
| Gene location on chromosome: | 15q21.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.4 |
| Normal role description: | Glycosyltransferase, that converts linear to branched poly-N-acetyllactosaminoglycans (in blood group I antigen formation) and mediates core 2 and core 4 O-glycan branching. It synthesizes all known mucin beta 6 N-acetylglucosaminides. Expression is downregulated in most cancers, that derive from mucus-secretory tissues. Reexpression results in inhibition of cell growth, migration and invasion. |